Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy

被引:5
|
作者
Tong, Yi Tat [1 ]
Lai, Zongshan [1 ]
Katz, Matthew H. G. [2 ]
Prakash, Laura R. [2 ]
Wang, Hua [3 ]
Chatterjee, Deyali [1 ]
Kim, Michael [2 ]
Tzeng, Ching-Wei D. [2 ]
Lee, Jeffrey E. E. [2 ]
Ikoma, Naruhiko [2 ]
Rashid, Asif [1 ]
Wolff, Robert A. [3 ]
Zhao, Dan [3 ]
Koay, Eugene J. [4 ]
Maitra, Anirban [1 ,5 ]
Wang, Huamin [1 ,5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
pancreatic cancer; neoadjuvant therapy; FOLFIRINOX; gemcitabine/nab-paclitaxel; tumor response grade; tumor stage; lymph node metastasis; survival; PREDICTS POOR-PROGNOSIS; NAB-PACLITAXEL; CANCER; SURVIVAL; PANCREATICODUODENECTOMY; CHEMORADIATION; INVASION;
D O I
10.3390/cancers15092608
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neoadjuvant FOLFIRINOX and gemcitabine/nab-paclitaxel (GemNP) therapies are increasingly used to treat patients with pancreatic ductal adenocarcinoma (PDAC). However, limited data are available on their clinicopathologic prognosticators. We examined the clinicopathologic factors and survival of 213 PDAC patients who received FOLFIRINOX with 71 patients who received GemNP. The FOLFIRINOX group was younger (p < 0.01) and had a higher rate of radiation (p = 0.049), higher rate of borderline resectable and locally advanced disease (p < 0.001), higher rate of Group 1 response (p = 0.045) and lower ypN stage (p = 0.03) than the GemNP group. Within FOLFIRINOX group, radiation was associated with decreased lymph node metastasis (p = 0.01) and lower ypN stage (p = 0.01). The tumor response group, ypT, ypN, LVI and PNI, correlated significantly with both DFS and OS (p < 0.05). Patients with the ypT0/T1a/T1b tumor had better DFS (p = 0.04) and OS (p = 0.03) than those with ypT1c tumor. In multivariate analysis, the tumor response group and ypN were independently prognostic factors for DFS and OS (p < 0.05). Our study demonstrated that the FOLFIRINOX group was younger and had a better pathologic response than the GemNP group and that the tumor response group, ypN, ypT, LVI and PNI, are significant prognostic factors for survival in these patients. Our results also suggest that the tumor size of 1.0 cm is a better cut off for ypT2. Our study highlights the importance of systemic pathologic examination and the reporting of post-treatment pancreatectomies.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Pathologic Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy
    Tong, Yi Tat
    Lai, Zongshan
    Katz, Matthew
    Prakash, Laura
    Wang, Hua
    Chatterjee, Deyali
    Kim, Michael
    Tzeng, Ching-Wei
    Lee, Jeffrey
    Ikoma, Naruhiko
    Rashid, Asif
    Wolff, Robert A.
    Zhao, Dan
    Koay, Eugene
    Maitra, Anirban
    Wang, Huamin
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1236 - 1236
  • [2] Pathologic Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy
    Tong, Yi Tat
    Lai, Zongshan
    Katz, Matthew
    Prakash, Laura
    Wang, Hua
    Chatterjee, Deyali
    Kim, Michael
    Tzeng, Ching-Wei
    Lee, Jeffrey
    Ikoma, Naruhiko
    Rashid, Asif
    Wolff, Robert A.
    Zhao, Dan
    Koay, Eugene
    Maitra, Anirban
    Wang, Huamin
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1236 - 1236
  • [3] Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX
    Peterson, Shawn L.
    Husnain, Muhammad
    Pollack, Terri
    Pimentel, Agustin
    Loaiza-Bonilla, Arturo
    Westendorf-Overley, Colleen
    Ratermann, Kelley
    Anthony, Lowell
    Desimone, Philip
    Goel, Gaurav
    Kudrimoti, Mahesh
    Dineen, Sean
    Tzeng, Ching-Wei D.
    Hosein, Peter J.
    ANTICANCER RESEARCH, 2018, 38 (07) : 4035 - 4039
  • [4] Survival outcomes based on sequence of therapy using FOLFIRINOX and nab-paclitaxel plus gemcitabine in metastatic pancreatic ductal adenocarcinoma
    Baron, Kelsey
    Nevala-Plagemann, Christopher Duane
    Moser, Justin
    Haaland, Benjamin
    Wang, Xuechen
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [5] Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel plus Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma
    Baron, Margaret Kelsey
    Wang, Xuechen
    Nevala-Plagemann, Christopher
    Moser, Justin C.
    Haaland, Benjamin
    Garrido-Laguna, Ignacio
    PANCREAS, 2021, 50 (06) : 796 - 802
  • [6] FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma
    Dhir, Mashaal
    Zenati, Mazen S.
    Hamad, Ahmad
    Singhi, Aatur D.
    Bahary, Nathan
    Hogg, Melissa E.
    Zeh, Herbert J., III
    Zureikat, Amer H.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (07) : 1896 - 1903
  • [7] FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma
    Mashaal Dhir
    Mazen S. Zenati
    Ahmad Hamad
    Aatur D. Singhi
    Nathan Bahary
    Melissa E. Hogg
    Herbert J. Zeh
    Amer H. Zureikat
    Annals of Surgical Oncology, 2018, 25 : 1896 - 1903
  • [8] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [9] Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma
    Pignon, Flore
    Turpin, Anthony
    Hentic, Olivia
    Coriat, Romain
    Salmon, Emma
    Baumgaertner, Isabelle
    Bertrand, Nicolas
    Levy, Philippe
    Rebours, Vinciane
    Hammel, Pascal
    de Mestier, Louis
    PANCREATOLOGY, 2021, 21 (06) : 1064 - 1070
  • [10] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199